Cevec To Upgrade Cap Technology

Cevec Pharmaceuticals (Cevec) has reported the closing of a E4m financing round that is aimed to finance the growth of human CAP technology. Creathor Venture Fonds and NRW.BANK led the round which included the participation from current investors and a group of private and institutional investors including the venture capital branch of Sparkasse KoelnBonn and ERP Startfonds of KfW bank.

The CAP Technology platform comprises human CAP and CAP-T expression systems and is used for the manufacture of complex biologics and therapeutic antibodies with human-like glycosylation and sialylation patterns.

Starting with transient protein expression using CAP-T up to stable expression using CAP cells, the CAP Technology is applicable from initial research ideas up to GMP-compliant manufacturing of clinical samples and market supplies.

Rainer Lichtenberger, CEO of Cevec, said: “We are delighted to have with Creathor Venture and NRW.BANK two first-class investors on board who value the unique strengths of the CAP Technology and provide the resources required to finance the company’s ambitious growth objectives.”

Karlheinz Schmelig, managing director at Creathor Venture Management and Aristotelis Nastos, NRW.BANK, said: “The global protein production market is ready for a high performance human expression system.”